NEW ALBANY, Ind., June 29, 2021 - Healthcare tech start-up RxLightning today announced that it has achieved Microsoft “IP Co-Sell Ready” status. As a Co-Sell Ready Microsoft partner, the company’s specialty drug enrollment solution will be jointly sold with Microsoft sales teams and in Microsoft’s commercial marketplace, opening the door to rapid expansion of the reach and deployment of RxLightning technology.
Founded in January 2020, RxLightning is a free-to-provider online platform that simplifies and automates the specialty medication enrollment process. The existing process, which is highly manual, frustrating and inefficient, can take weeks or months before a patient can get started on critical therapies. RxLightning reduces that time significantly, to just 2–5 days. The space is ripe for RxLightning’s innovation, as the challenges surrounding the current process are forecasted to only get worse with specialty medications – currently a $225 billion market – accounting for 70% of all new drugs hitting the market.
The Microsoft Co-Sell Program enables Microsoft and its partners to provide comprehensive solutions in a collaborative, better-together selling model to drive joint sales, revenue and mutual customer success. To achieve co-sell status with Microsoft, partners must pass a thorough technical verification process, have a commercial-ready product, an engaged sales team and a solid go-to-market strategy. After having passed all the requirements, RxLightning has been confirmed as an “IP Co-Sell Ready” Microsoft partner.
“Being approved as Microsoft IP Co-Sell Ready is a potential game-changer for us, and we’re honored to have achieved this status and to be among such a select group of software partners,” said Julia Regan, founder and CEO of RxLightning. “The current specialty medication enrollment process is archaic, cumbersome on practices and allows too much room for error – all of which ultimately impact the patient and too often cause significant delays in treatments. With Microsoft’s sales and partner channels, we are one step closer to ensuring that every patient gets accelerated access to the therapies they need, every time.”
Founded in New Albany, Indiana in 2020, RxLightning digitizes, automates and streamlines the historically complicated manual enrollment process of starting a patient on specialty medications. Specialty medications are expected to account for 65% of new medication launches through 2023. With RxLightning, healthcare providers can quickly and easily complete the enrollment process for every specialty medication in every therapeutic area, helping reduce paperwork, streamline communication and accelerate the speed of therapy for patients. Learn more at rxlightning.com.
